Entrada Therapeutics, Inc. stock is down -17.24% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October. 100% of analysts rate it a buy.
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for Duchenne muscular dystrophy and myotonic dstrophy type 1.